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Abstract Metformin was found to affect plasma levels of
some pituitary hormones. This study was aimed at inves-
tigating whether metformin treatment has an impact on
plasma prolactin levels in bromocriptine-treated patients
with hyperprolactinaemia and impaired glucose tolerance.
The study included 27 patients with hyperprolactinaemia,
who had been treated for at least 6 months with bromo-
criptine. Based on prolactin levels, bromocriptine-treated
patients were divided into two groups: patients with ele-
vated (group A, n = 12) and patients with normal (group
B, n = 15) prolactin levels. The control group included 16
age-, sex- and weight-matched hyperprolactinaemia-free
individuals with impaired glucose tolerance (group C).The
lipid profile, fasting plasma glucose levels, the homeostatic
model assessment of insulin resistance ratio (HOMA-IR),
glycated haemoglobin, as well as plasma levels of prolac-
tin, thyrotropin and insulin-like growth factor-1 (IGF-1)
were assessed at baseline and after 4 months of metformin
treatment (2.55–3 g daily). In all treatment groups, met-
formin reduced HOMA-IR, plasma triglycerides and 2-h
postchallenge plasma glucose. In patients with hyperpro-
lactinaemia, but not in the other groups of patients, met-
formin slightly reduced plasma levels of prolactin, and this
effect correlated weakly with the metabolic effects of this
drug. Our study shows that metformin decreases plasma
prolactin levels only in patients with elevated levels of this
hormone. The obtained results suggest that metformin
treatment may bring some benefits to hyperprolactinaemic
patients with coexisting glucose metabolism disturbances
already receiving dopamine agonist therapy.
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In recent years, it has become clear that elevated prolactin
levels are often associated with hyperinsulinaemia, insulin
resistance, atherogenic dyslipidaemia, subclinical athero-
sclerosis and endothelial dysfunction [1–6]. A quick-
release form of bromocriptine was found to reduce plasma
glucose levels, glycated haemoglobin, free fatty acids and
triglycerides, and, therefore, was approved for the treat-
ment of type 2 diabetes [7–9]. Another dopamine receptor
agonist, cabergoline decreased waist circumference,
plasma lipids, glycated haemoglobin, insulin and the
homeostatic model assessment of insulin resistance
(HOMA-IR) and this effect, observed regardless of the
degree of reduction in prolactin levels, was dose-dependent
[10]. Moreover, long-term cabergoline reduced the preva-
lence of metabolic syndrome and cardiometabolic risk
associated with visceral obesity [11].
There is some evidence that metformin, considered the
first-line treatment for type 2 diabetes mellitus [12] and
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often used in other conditions associated with insulin
resistance [13], may affect pituitary hormone secretion.
The drug administered to patients with untreated hypo-
thyroidism or to hypothyroid patients effectively treated
with levothyroxine reduced plasma thyrotropin levels,
often to subnormal levels [14–16]. Metformin treatment of
women with polycystic ovary syndrome was associated in
some studies with a reduction in circulating levels of
luteinizing hormone and the luteinizing hormone/follicle-
stimulating hormone ratio [17–20]. Finally, in the same
disorder, metformin administered alone or in combination
with simvastatin, decreased circulating levels of prolactin
[19–22]. Interestingly, recently we observed a patient with
resistance to thyroid hormone, in whom metformin reduced
plasma thyrotropin levels, probably by enhancing the effect
of thyroid hormones in the pituitary [23].
However, to the best of our knowledge, prolactin-low-
ering effect of metformin was observed only in patients
with polycystic ovary syndrome, and these patients were
not treated with dopamine receptor agonists. Therefore, the
aim of this study was to assess whether metformin
administered to bromocriptine-treated patients with hy-
perprolactinaemia and impaired glucose tolerance affects
plasma prolactin levels.
Materials and methods
The participants of the study were recruited among hyper-
prolactinaemic subjects treated for at least 6 months with a
constant dose of bromocriptine (2.5–10 mg daily). These
individuals, initially diagnosed and treated in local endocrine
outpatient clinics, were screened in our department for the
presence of metabolic abnormalities. To be included into the
study, the participants had to meet the following inclusion
criteria of impaired glucose tolerance: (1) fasting plasma
glucose less than 100 mg/dl and (2) plasma glucose concen-
tration 2 h after a 75-g oral glucose load at least 140 mg/dl but
less than 200 mg/dl. The exclusion criteria were as follows:
mixed pituitary tumours (secreting prolactin and other pitui-
tary hormones), macroprolactinoma, other hormonally active
and non-functioning pituitary adenomas, primary hypogo-
nadism, impaired renal or hepatic function, thyroid disorders,
polycystic ovary syndrome, pregnancy or lactation, macro-
prolactinaemia or treatment with other drugs known to affect
plasma prolactin levels. All enrolled patients provided their
written informed consent for the investigation, and the study
was performed according to the Declaration of Helsinki. The
local ethics committee approved the study protocol. Based on
prolactin levels, bromocriptine-treated patients were divided
into two groups: patients with elevated (group A, n = 12) and
patients with normal (group B, n = 15) circulating prolactin
levels. We also recruited 16 age-, sex- and weight-matched
control subjects with impaired glucose tolerance and a nega-
tive history of hyperprolactinaemia (group C). All included
patients were treated with metformin. In each treatment group,
the dose of this agent was gradually (over 4 weeks) increased
from 0.5 g once daily to a maximum effective daily dose
(2.55–3.0 g divided into three doses per day), and this final
dose of metformin was administered for 4 months.
Throughout the study, patients received bromocriptine at the
same dose as before the beginning of the study and complied
with dietary recommendations. Patients who were already
taking other drugs kept their pharmacologic schedule constant
during the study.
Blood samples were collected from the antecubital vein at 8
am after an overnight 12-h fasting. Moreover, glucose levels
were measured in samples obtained 2 h after the oral ingestion
of 75 g of glucose. To minimise analytical errors, all assays
were carried out in duplicate. Plasma lipids, glucose and
insulin levels were assayed by routine laboratory techniques
(bioMerieux France; Beckman, Palo Alto, CA, USA; Instru-
ments GmbH, Marburg, Germany). The homeostatic model
assessment of insulin resistance (HOMA-IR) was calculated
by the formula: HOMA-IR = fasting plasma glucose (mg/dl)
*immunoreactive insulin (lU/ml)/405 [24]. Glycated hae-
moglobin was determined using DCA 2000 analyser (Bayer
Ames Technicon, Tarrytown, NY). Plasma prolactin and
insulin-like growth factor-1 (IGF-1) were determined by
enzyme-linked immunosorbent assay (DRG Instruments
GmbH, Marburg, Germany). Plasma levels of thyrotropin
were measured using an electrochemiluminescence immu-
noassay method (Roche Diagnostics, Lewes, UK). Intra- and
inter-assay coefficients of variation were less than 6.2 and
8.5 %, respectively.
The distribution of the variables was analysed using the
Kolmogorov–Smirnov test. To fit a normal distribution
curve, log transformation was used for the non-normal
variables. Comparisons between the groups were per-
formed using analysis of covariance followed by Bonfer-
roni post hoc tests after consideration of age, sex, smoking,
body mass index, waist-hip ratio, blood pressure, duration
of bromocriptine treatment and bromocriptine dose as
potential confounders. The differences between the means
of variables within the same treatment group were analysed
with Student’s paired t test. Categorical variables were
analysed by v2test. Correlations were assessed using Ken-
dall’s tau test. Values of p \ 0.05 were considered statis-
tically significant.
Results
All treatment groups did not differ significantly in terms of
demographic and anthropometric data (age, sex, smoking,
body mass index, waist-hip ratio and blood pressure)
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(Table 1). No significant differences were observed with
regard to medical background and baseline laboratory
results. Expectedly, circulating prolactin levels were higher
in group A than in the other groups of patients. Two
patients (one from group B and one from group C) stopped
participating in the study because of metformin-induced
diarrhoea, nausea and increased flatulence.
In all groups, metformin treatment led to a reduction in
HOMA-IR, glycated haemoglobin, plasma triglycerides
and 2-h postchallenge plasma glucose (Table 2). In patients
with impaired glucose tolerance and normal prolactin
levels (groups B and C), metformin produced no effect on
plasma levels of the measured hormones. In patients with
hyperprolactinaemia, metformin reduced plasma levels of
prolactin, but did not affect circulating levels of thyrotropin
and IGF-1. Between-group comparisons showed that the
effect of metformin on plasma prolactin was stronger in
group A than in groups B and C. However, at the end of the
study, prolactin levels in group A were still higher than the
remaining groups of patients (Table 2). The effect of
metformin on prolactin levels in group A, as well as on 2-h
postchallenge plasma glucose, glycated haemoglobin and
HOMA-IR in all treatment groups tended to be more pro-
nounced (p values between 0.056 and 0.096) in patients
treated with 3 g than with 2.55 g of metformin daily (data
not shown).
At entry, prolactin levels correlated weakly with
HOMA-IR, plasma triglycerides and 2-h postchallenge
plasma glucose (r values between 0.22 [p \ 0.01] and 0.32
[p \ 0.001]). In patients with hyperprolactinaemia, but not






prolactin levels (Group B)
Control group
(Group C)
Number of patients 12 14 15
Age [years; mean (SD)] 32 (3) 31 (4) 32 (4)
Women [%] 75 71 80
Smokers [%] 25 29 27
Duration of bromocriptine treatment [months; mean (SD)] 11 (2)*** 12 (3)*** 0 (0)
Bromocriptine dose [mg; mean (SD)] 6.4 (1.3)*** 6.2 (1.2)*** 0 (0)
Body mass index [kg/m2; mean (SD)]a 28.3 (2.4) 28.9 (2.2) 27.9 (2.0)
Waist-hip ratio [mean (SD)]b 0.92 (0.08) 0.94 (0.07) 0.91 (0.06)
Systolic blood pressure [mmHg; mean (SD)]c 129 (10) 127 (11) 125 (9)
Diastolic blood pressure [mmHg; mean (SD)]c 84 (4) 81 (3) 82 (3)
Hypertension [%]d 25 21 20
Prolactin-secreting tumours [%] 67*** 57*** 0
Fasting glucose [mmol/L; mean (SD)] 4.81 (0.25) 4.72 (0.23) 4.77 (0.21)
2-h postchallenge plasma glucose [mmol/L; mean (SD)] 9.72 (0.63) 9.17 (0.80) 9.32 (0.70)
HOMA-IR [mean (SD)] 5.0 (0.5) 4.7 (0.4) 4.6 (0.5)
Glycated haemoglobin [%; mean (SD)] 6.1 (0.2) 6.0 (0.2) 6.0 (0.2)
Total cholesterol [mmol/L; mean (SD)] 5.56 (0.61) 5.62 (0.52) 5.51 (0.58)
LDL-cholesterol [mmol/L; mean (SD)] 3.31 (0.42) 3.25 (0.32) 3.19 (0.28)
HDL-cholesterol [mmol/L; mean (SD)] 1.12 (0.18) 1.25 (0.15) 1.19 (0.16)
Triglycerides [mmol/L; mean (SD)] 2.56 (0.38) 2.43 (0.35) 2.40 (0.31)
Prolactin [ng/mL; mean (SD)] 46 (10)***### 12 (4) 14 (3)
IGF-1 [ng/mL; mean (SD)] 235 (61) 195 (43) 189 (41)
Thyrotropin [mIU/L; mean (SD)] 2.0 (0.7) 1.5 (0.4) 1.4 (0.5)
Only data of individuals who completed the study were included in the final analyses
a Weight in kilograms divided by the square of the height in meters [25]
b The ratio of the circumference of the waist (the midpoint between the lower margin of the last palpable rib and the top of the iliac crest) to that
of the hips (the widest portion of the buttocks) [25]
c Average of two blood pressure measurements taken in the sitting position, spaced 2 min apart,after at least 5 min of rest [26]
d Blood pressure greater than 140/90 on two or more blood pressure readings taken at each of two or more visits after initial screening [26]
*** p \ 0.001 versus control subjects (group C)
### p \ 0.001 versus bromocriptine-treated patients with normal prolactin levels (group B)
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in groups B and C, the effect of metformin on circulating
prolactin levels correlated with baseline prolactin levels
(r = 0.51, p \ 0.001), as well as weakly with the effect of
this drug on HOMA-IR (r = 0.34, p \ 0.001), 2-h post-
challenge plasma glucose (r = 0.25, p \ 0.01) and
triglycerides (r = 0.29, p \ 0.01). The effect of metformin
on glucose homeostasis markers, plasma lipids and the
investigated pituitary hormones correlated neither with the
duration of bromocriptine treatment nor with bromocrip-
tine dose.
Table 2 The effect of metformin on glucose homeostasis markers, plasma lipids and the investigated pituitary hormones in bromocriptine-
treated patients and the control group
Variable Bromocriptine-treated patients
with hyperprolactinaemia (Group A)
Bromocriptine-treated patients with
normal prolactin levels (Group B)
Control group (Group C)
Mean (SD) [D %] Mean (SD) [D %] Mean (SD) [D %]
Fasting glucose [mmol/L]
Baseline 4.81 (0.25) 4.72 (0.23) 4.77 (0.21)
After 4 months 4.56 (0.30) [-5] 4.51 (0.24) [-4] 4.58 (0.26) [-4]
2-h postchallenge plasma glucose [mmol/L]
Baseline 9.72 (0.63) 9.17 (0.80) 9.32 (0.70)
After 4 months 7.94 (0.56) [-18]&&& 7.78 (0.52) [-15]&&& 7.72 (0.76) [-17]&&&
HOMA-IR
Baseline 5.0 (0.5) 4.7 (0.4) 4.6 (0.5)
After 4 months 3.4 (0.4) [-32]&&& 3.1 (0.4) [-34]&&& 3.2 (0.4) [-30]&&&
Glycated haemoglobin [%]
Baseline 6.1 (0.2) 6.0 (0.2) 6.0 (0.2)
After 4 months 5.5 (0.2) [-10]&&& 5.6 (0.2) [-7]&& 5.5 (0.3) [-8]&&
Total cholesterol [mmol/L]
Baseline 5.56 (0.61) 5.62 (0.52) 5.51 (0.58)
After 4 months 5.38 (0.58) [-3] 5.34 (0.48) [-5] 5.28 (0.51) [-4]
LDL-cholesterol [mmol/L]
Baseline 3.31 (0.42) 3.25 (0.32) 3.19 (0.28)
After 4 months 3.16 (0.38) [-5] 3.08 (0.29) [-5] 3.01 (0.26) [-6]
HDL-cholesterol [mmol/L]
Baseline 1.12 (0.18) 1.25 (0.15) 1.19 (0.16)
After 4 months 1.24 (0.16) [11] 1.35 (0.18) [8] 1.30 (0.14) [9]
Triglycerides [mmol/L]
Baseline 2.56 (0.38) 2.43 (0.35) 2.40 (0.31)
After 4 months 2.16 (0.28) [-16]& 2.06 (0.32) [-15]& 2.08 (0.34) [-13]&
Prolactin [ng/mL]
Baseline 46 (10)***### 12 (4) 14 (3)
After 4 months 34 (8) [-26]***###& 11 (4) [-8] 12 (3) [-14]
IGF-1 [ng/mL]
Baseline 235 (61) 195 (43) 189 (41)
After 4 months 220 (62) [-6] 185 (40) [-5] 176 (29) [-7]
Thyrotropin [mIU/L]
Baseline 2.0 (0.7) 1.5 (0.4) 1.4 (0.5)
After 4 months 1.6 (0.6) [-20] 1.3 [-13] 1.2 [-14]
Only data of individuals who completed the study were included in the final analyses
*** p \ 0.001 versus control subjects (group C)
### p \ 0.001 versus bromocriptine-treated patients with normal prolactin levels (group B)
& p \ 0.05
&& p \ 0.01
&&& p \ 0.001 versus baseline value
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Discussion
The major finding of this study is that metformin reduced
prolactin levels only in patients with hyperprolactinaemia,
while this effect was not observed in subjects with normal
prolactin levels. Considering the exclusion criteria (liver
and renal failure), our results indicate that the impact of
metformin on circulating levels of this hormone is notice-
able only if its pituitary production is increased. In line
with this hypothesis, metformin did not change plasma
levels of thyrotropin and IGF-1, the baseline levels of
which were within the reference range.
Although higher than in the Diabetes Prevention Pro-
gramme (1.7 g daily) [27], metformin dose in our study was
similar to the maximum dose of metformin (2.55 g daily),
used by more than half of patients in the United Kingdom
Prospective Diabetes Study, the largest clinical research
study into diabetes ever conducted at the time [28]. At the
same doses as in the present study, metformin, administered
because of coexistent type 2 diabetes, reduced androgen
levels in women with non-classic congenital adrenal
hyperplasia [29] as well as thyrotropin and thyroid hormone
levels in a patient with resistance to thyroid hormone [30].
Also in patients with impaired glucose tolerance, high-dose
metformin treatment was well tolerated and produced mul-
tidirectional pleiotropic effects [31, 32], while in individuals
with insulin resistance it produced the strongest effect on
glycaemic control and plasma lipids [33]. Interestingly, the
impact of metformin on prolactin levels, as well as on glu-
cose homeostasis was a bit stronger if administered at higher
(3 g) than lower (2.55 g) daily dose, suggesting that this
effect is dose-dependent. The difference, however, did not
reach the level of significance, probably because of a small
number of patients treated with each dose.
It should be stressed that the prolactin-lowering effect in
patients ineffectively treated with bromocriptine was at
most moderate and post-treatment prolactin levels still
exceeded normal values. Taking into account that dopa-
mine agonists are the drugs of choice in the treatment of
elevated prolactin levels [34], and markedly reduce car-
diometabolic risk in hyperprolactinaemic patients [7–11], it
seems that a proper bromocriptine dose adjustment or
replacing bromocriptine with cabergoline in Group A
patients would have produced greater effects on prolactin
levels and on metabolic parameters than metformin addi-
tion. Therefore, metformin should be rather reserved for
the treatment of coexisting glucose metabolism abnor-
malities and eventually of hyperprolactinaemia if they are
not reversed by dopamine agonist therapy. Our results also
suggest that in normoprolactinaemic patients treated with
bromocriptine, the dose of this drug does not require a
reduction, if a patient has to be treated with metformin
because of coexisting glucose metabolism abnormalities.
We included individuals with concomitant impaired
glucose tolerance, because from a cardiometabolic point of
view these patients seem good candidates for metformin
treatment. In the Diabetes Prevention Programme [27] and
a Chinese study [35], metformin decreased the incidence of
type 2 diabetes in subjects with impaired glucose tolerance,
only some of whom had coexistent impaired fasting glu-
cose. Moreover, the investigated group of patients is
probably particularly prone to the earlier development and
faster progression of atherosclerosis. Hyperprolactinaemia
is associated with preclinical atherosclerosis, while patients
with hyperprolactinaemia might experience cardiovascular
disease in the long term [36]. Impaired glucose tolerance is
characterised by a greater risk of cardiovascular disorder
than isolated impaired fasting glucose. After adjusting for
hypertension and dyslipidaemia, only impaired glucose
tolerance remains an independent risk factor of cardio-
vascular events or death [37]. Moreover, the association
between impaired glucose tolerance and diabetes devel-
opment is better documented than for impaired fasting
glucose [13]. Therefore, although the effect on prolactin
levels was relatively mild and limited to patients with
elevated prolactin levels, metformin may be useful in hy-
perprolactinaemic patients at high risk of diabetes and
cardiovascular disease. Unfortunately, the study protocol
does not allow us to conclude whether metformin produces
a similar effect in hyperprolactinaemic patients with no
evidence of hyperinsulinaemia, glucose abnormalities and
metabolic syndrome.
It cannot be excluded that metformin treatment may also
bring some benefits to hyperprolactinaemic patients failing
to achieve normal prolactin level on maximally tolerated
doses of dopamine agonist, who are poor operative candi-
dates or decline surgery. This question requires, however,
further studies. We excluded individuals with macropro-
lactinoma who, because of potentially aggressive tumour
behaviour, should be treated with cabergoline rather than
with bromocriptine [38]. Moreover, in patients with large
prolactinomas, the initial prolactin level may be read
erroneously as normal or only mildly elevated (‘‘the hook
effect’’) [39]. Finally, large prolactin-secreting pituitary
tumours often (even in 78 % of patients) lead to the
development of hypopituitarism; the gonadal and somato-
tropic axes being the most frequently affected [40]. The
eventual presence and severity of secondary hypogonadism
and other manifestations of hypopituitarism might have
affected our findings.
The obtained results may be theoretically attributed to a
time-dependent effect of bromocriptine treatment but this
explanation seems much less probable. Eligible patients were
enrolled in the study only if they were treated with a constant
dose of bromocriptine for at least 6 months (on average for
11 months) before the study onset and no changes in dosage
246 Endocrine (2015) 49:242–249
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were allowed during the entire study period. A reduction in
circulating prolactin levels was observed in a subgroup of
patients in whom hyperprolactinaemia was unrelated to pro-
lactinoma and, therefore, could not be associated with a
decrease in tumour size and/or tumour apoplexy. Finally,
previously we followed 11 patients meeting the inclusion
criteria of group A but not receiving metformin, in whom,
despite elevated prolactin levels, bromocriptine treatment was
continued in the same dose. In this group of patients, com-
parable to group A with respect to age, sex, body weight and
bromocriptine dose, 6 months later, circulating prolactin
levels did not differ from baseline values [Krysiak et al.,
unpublished observations].
Another interesting question is metformin use in hy-
perprolactinaemic subjects not treated with dopamine
agonists. Our study indirectly suggests that metformin may
decrease prolactin levels also in this group of patients
because its impact on circulating prolactin levels correlated
with baseline prolactin levels, but not with the duration and
dosage of bromocriptine treatment. This interesting
hypothesis will be verified in our future research.
The study protocol does not allow us to unequivocally
explain the mechanism responsible for this action of met-
formin. Metformin may change the affinity and/or the
number of dopamine receptors or of receptors for other
compounds regulating production, secretion and metabolism
of prolactin, may enhance gastrointestinal absorption and/or
metabolism of bromocriptine, as well as may directly affect
prolactin pharmacokinetics. Interestingly, animal studies
carried out in our laboratory evidenced that metformin
penetrates the blood–brain barrier, and its content in the
pituitary is higher than in any other brain structure [41]. In
the light of these results, it seems that the pituitary is an
important target for metformin action and that the prolactin-
lowering effect of this agent results, at least in part, from its
action at the level of pituitary lactotropes. Taking into
account that this drug was found to reduce plasma levels of
other pituitary hormones [14–18, 23], it may be assumed that
metformin affects the function of different types of pituitary
cells, provided their secretory function is enhanced. In
agreement with this hypothesis, in the study by Cappelli et al.
[14], the authors did not find any changes in plasma thyrot-
ropin levels in metformin-treated patients with normal
hypothalamic-pituitary-thyroid axis activity. Although we
cannot totally exclude the possibility that metformin affects
pharmacokinetics of bromocriptine, this explanation is much
less likely. In our study, this drug did not reduce plasma
prolactin levels in group B, treated like group A, with bro-
mocriptine. Moreover, metformin was found to reduce, not
to improve, absorption of vitamin B12, folates, amino acids,
glucose and some drugs [42]. The obtained results cannot be
also explained by a reduction in circulating levels of
luteinizing hormone and the luteinizing hormone/follicle-
stimulating hormone ratio, as demonstrated in patients with
polycystic ovary syndrome [19, 20], because this syndrome
belonged to the exclusion criteria, while microprolactinoma,
traumatic brain injury and primary empty sella syndrome
responsible for hyperprolactinaemia in our study are char-
acterised by normal or reduced gonadotropin levels [38, 39].
Metformin action on prolactin in group A correlated with
the degree of a reduction in HOMA-IR, 2-h postchallenge
plasma glucose and triglycerides. Although the aforemen-
tioned correlations were weak, their presence suggests that
some signal pathways regulating prolactin production and
release, and signal pathways affected by insulin may overlap
to some extent. The complex regulation of prolactin secretion
and release, involving both direct and indirect mechanisms
[43, 44] and their mutual interactions may explain why these
correlations were absent in normoprolactinemic patients.
This study has some limitations. The most important of
them is a small number of participants and the short
duration of treatment, limiting the statistical significance of
the findings. Moreover, all hyperprolactinaemic patients
received bromocriptine. It cannot be completely excluded
that the effect of metformin treatment on plasma prolactin
levels is different in patients with elevated prolactin levels
receiving other dopaminergic agents and/or, as mentioned
above, in non-treated patients. Finally, all our patients had
coexistent impaired glucose tolerance. Therefore, the
question whether a similar effect is observed in patients
with other glucose metabolism abnormalities (type 2 dia-
betes and impaired fasting glucose), or in patients with
normal glucose tolerance remains still open.
To sum up, this study shows that metformin slightly
reduces elevated prolactin levels in patients chronically
treated with bromocriptine. This effect, correlating weakly
with metabolic effects of bromocriptine, suggests that met-
formin may be useful in the management of hyperprolacti-
naemic patients with coexisting glucose metabolism
disturbances already receiving dopamine agonist therapy.
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